# Dulaglutide for type 2 diabetes.

> PubMed lists PMID 30410215 in Australian prescriber as Journal Article, Review, with publication-date metadata of 2018-09-11 (day precision). PeptideScanner associated the retained record with the identity slug dulaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-30410215-dulaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-02-06
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30410215-dulaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-30410215-dulaglutide-v1.json
- Content SHA-256: `c313696927d0900a28a1f14ee41fd8a18d5d5723bd8dcbdf2ad512c31976bea5`

## Claims and source pins

### Headline

Dulaglutide for type 2 diabetes. ([`pubmed-observation-pmid-30410215-2021-02-06-030c2700a1b0`](#source-pubmed-observation-pmid-30410215-2021-02-06-030c2700a1b0))

### Summary

PubMed lists PMID 30410215 in Australian prescriber as Journal Article, Review, with publication-date metadata of 2018-09-11 (day precision). PeptideScanner associated the retained record with the identity slug dulaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30410215-2021-02-06-030c2700a1b0`](#source-pubmed-observation-pmid-30410215-2021-02-06-030c2700a1b0))

### Paragraph 1

PubMed lists PMID 30410215 in Australian prescriber as Journal Article, Review, with publication-date metadata of 2018-09-11 (day precision). PeptideScanner associated the retained record with the identity slug dulaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-30410215-2021-02-06-030c2700a1b0`](#source-pubmed-observation-pmid-30410215-2021-02-06-030c2700a1b0))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30410215-2021-02-06-030c2700a1b0`](#source-pubmed-observation-pmid-30410215-2021-02-06-030c2700a1b0))

## Sources

<a id="source-pubmed-observation-pmid-30410215-2021-02-06-030c2700a1b0"></a>
- **Dulaglutide for type 2 diabetes. · retained source version 1:2021-02-06:current:030c2700a1b0ee27b9f47b8ab46a80a1b75ea03424fa17ca65e8052db9a5aae4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30410215/) (`pubmed-observation-pmid-30410215-2021-02-06-030c2700a1b0`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Dulaglutide for type 2 diabetes." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-30410215-dulaglutide-v1.json SHA-256: c313696927d0900a28a1f14ee41fd8a18d5d5723bd8dcbdf2ad512c31976bea5.